What Titan Pharmaceuticals does

Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) is a development-stage specialty pharmaceutical company incorporated in Delaware in 1992 and headquartered in South San Francisco, California, with a headcount of 11–50. Its core asset is the ProNeura® platform — a proprietary long-term, continuous drug-delivery technology consisting of subdermal implants made from an ethylene-vinyl acetate (EVA) matrix combined with a drug substance, designed to release medication steadily over six months or longer from a single outpatient insertion procedure. The first ProNeura-based product, Probuphine® (buprenorphine implant), received regulatory approval in the United States, Canada, and the European Union (where it is marketed as Sixmo™) for maintenance treatment of opioid use disorder in clinically stable patients on low-dose oral buprenorphine.

Titan's business model has shifted materially over the past five years. The company discontinued US commercialization of Probuphine in Q4 2020 and sold the product rights outright in September 2023, ending its commercial-stage revenue. Its current monetization approach is platform-IP licensing: in December 2022, Titan executed an exclusive US license of certain ophthalmic patent applications to Ocular Therapeutix in exchange for a $50,000 upfront fee and up to $135,000 in milestones tied to patent issuance and first commercial sale. The company has also raised $1.6M in 2025 through two private placements of convertible preferred stock to Blue Harbour Asset Management. In December 2021, Titan announced a formal review of strategic alternatives — including acquisition, merger, reverse merger, asset sale, or licensing transactions — indicating the company is positioning itself as a transaction candidate rather than an operating growth platform.

Name

Titan Pharmaceuticals

Legal name

Titan Pharmaceuticals, Inc.

Website

https://titanpharm.com

Company type

Public

Founded year

1992

Operating status

Operating

Headcount range

11–50 employees

Short description

Titan Pharmaceuticals is a development-stage specialty pharmaceutical company that develops the ProNeura long-term subdermal drug-delivery platform and has historically commercialized the Probuphine buprenorphine implant for opioid use disorder. After divesting its commercial product in 2023, it now monetizes residual IP via outbound licensing while exploring strategic alternatives.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (32541), Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Medication-Assisted Treatment (MAT) & Opioid Treatment Programs (OTPs) (HLAFACAG)

akta.pro secondary industries

Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF), Specialty Pharmacy & Complex Therapy Management Platforms (HLACAKAG)

Keywords

• Drug delivery platform
• Subdermal implants
• Opioid use disorder treatment
• Pharmaceutical development
• Buprenorphine implant

Headquarters

HQ city

South San Francisco

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Others

Revenue model

1. Product Sales (Historical): Titan previously generated revenue from commercializing Probuphine (buprenorphine implant) in the US, Canada, and EU for opioid use disorder treatment. The company discontinued US commercialization in Q4 2020 and sold the product in September 2023. Product continues to be commercialized in the EU under the brand Sixmo by the acquirer.
2. Licensing Revenue: Titan generates licensing revenue from its intellectual property. In December 2022, the company entered a licensing agreement with Ocular Therapeutix for ophthalmic patent applications, receiving a $50,000 upfront fee with potential milestone payments of up to $135,000.
3. Private Placement Financing: The company has raised capital through private placements of convertible preferred stock to Blue Harbour Asset Management, including $1 million in Series B (April 2025) and $600,000 in Series C (June 2025).

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Titan Pharmaceuticals develops proprietary therapeutics using its ProNeura long-term, continuous drug delivery platform, which consists of small, solid subdermal implants made from ethylene-vinyl acetate (EVA) and a drug substance. The platform provides non-fluctuating medication levels over six months or longer from a single outpatient insertion procedure. Its first commercial product, Probuphine (buprenorphine implant), was approved for opioid use disorder maintenance treatment in the US, Canada, and EU; the company has since divested that product and now focuses on licensing the platform and exploring strategic alternatives.

Product overview

Titan Pharmaceuticals is a development stage company developing proprietary therapeutics with its ProNeura® long-term, continuous drug delivery technology. The technology consists of subdermal implants that provide continuous drug release over six months or longer. The company's first approved product was Probuphine® (marketed as Sixmo™ in the EU), a buprenorphine implant for opioid use disorder. In December 2022, Titan entered a licensing agreement with Ocular Therapeutix for certain patent applications covering ophthalmic uses. Titan is currently exploring strategic alternatives following a December 2021 announcement to enhance shareholder value.

Differentiator

Problem solved

Functional benefit

Brands

• ProNeura: Titan's proprietary long-term, drug delivery platform that provides continuous drug release over a period of six months or longer. Consists of a small, solid implant made from ethylene-vinyl acetate (EVA) and a drug substance, administered sub-dermally.

Products and services

• ProNeura

Segments1 record

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

One partnership is on record.

• Ocular Therapeutix, Inc.coreOEM/ Whitelabel/ Licensing Partner · 6 December 2022Titan granted Ocular Therapeutix an exclusive license to certain patent applications for ophthalmic uses in both humans and nonhuman animals in the United States. Ocular pays Titan a $50,000 upfront fee plus milestone payments upon issuance of first Licensed Patent ($35,000) and First Commercial Sale ($100,000). Ocular has sole rights to prosecute and maintain the licensed patents.

Scale indicators3 records

Recent moves7 records

Expansion highlights4 records

Broad incumbents

• Alkermes: Alkermes developed and commercializes VIVITROL (once-monthly injectable naltrexone), a long-acting depot product for opioid and alcohol use disorder. Comparable as a long-acting injectable/implantable-format player in the substance use disorder space.
• Indivior: Indivior is the market leader in opioid use disorder treatment via Suboxone (sublingual buprenorphine/naloxone) and SUBLOCADE (once-monthly subcutaneous buprenorphine depot), competing directly in the long-acting buprenorphine adherence category that Titan's ProNeura implant also targets.
• Pacira BioSciences: Pacira is the leader in long-acting local anesthetic depots (EXPAREL) using multivesicular liposome extended-release technology. Comparable as an established long-acting drug-delivery platform company that monetized a sustained-release technology across multiple indications.

Direct peers

• Camurus: Camurus develops long-acting FluidCrystal and other depot injection technologies for substance use disorder (e.g., Buvidal weekly/monthly subcutaneous buprenorphine). Directly comparable as a long-acting drug-delivery platform company targeting the same OUD adherence use case as ProNeura.
• Braeburn Pharmaceuticals: Braeburn held US commercialization rights to Probuphine (buprenorphine implant) and is the most direct historical competitor in the long-acting buprenorphine implant space for opioid use disorder — same product, same patient population, same delivery mechanism.

Emerging players

• Ocular Therapeutix: Ocular Therapeutix is Titan's exclusive licensee for ophthalmic applications of certain ProNeura-related patents (Dec 2022 agreement). Directly comparable as a party commercializing technology derived from Titan's IP and as a small-cap specialty drug-delivery company using hydrogel/pegylated sustained-release platforms.
• Heron Therapeutics: Heron Therapeutics develops long-acting biodegradable polymer-based injectable products (e.g., ZYNRELEF, APONVIE). Comparable as a small-cap specialty pharma using extended-release polymer delivery technology for chronic conditions.
• Lipocine: Lipocine is a small-cap specialty pharma developing oral and long-acting delivery formulations for CNS and endocrine indications. Comparable as a micro-cap reformulation/drug-delivery platform company pursuing licensing-driven business model.
• BioDelivery Sciences International (BDSI): BDSI commercialized buprenorphine-based products (BUNAVAIL, BELBUCA) for pain and OUD, competing in the same molecule class as Probuphine. Comparable as a specialty pharma focused on reformulated/extended-delivery buprenorphine assets.

Regional players

• Adapt Pharma / Emergent BioSolutions (Narcan franchise): Emergent (via the Narcan nasal spray franchise) operates in the opioid overdose/use-disorder treatment ecosystem alongside Titan's OUD focus. Comparable as a specialty pharma addressing the broader opioid crisis treatment continuum.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat2 records

Key risks6 records

Key highlights5 records

Customer concentration

• Xx.com/titanpharma
• LinkedInlinkedin.com/company/titan-pharmaceuticals

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds8 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Titan Pharmaceuticals